Loomis Sayles & Co. L P Sells 18,341 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Loomis Sayles & Co. L P lowered its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 1.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,243,267 shares of the company's stock after selling 18,341 shares during the period. Loomis Sayles & Co. L P owned about 2.38% of PROCEPT BioRobotics worth $99,610,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Values First Advisors Inc. bought a new position in shares of PROCEPT BioRobotics during the 3rd quarter worth approximately $27,000. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of PROCEPT BioRobotics during the second quarter valued at approximately $36,000. Quest Partners LLC lifted its holdings in PROCEPT BioRobotics by 2,492.3% during the second quarter. Quest Partners LLC now owns 674 shares of the company's stock worth $41,000 after acquiring an additional 648 shares during the period. Nisa Investment Advisors LLC boosted its position in PROCEPT BioRobotics by 178.3% in the third quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company's stock worth $89,000 after purchasing an additional 713 shares during the last quarter. Finally, Sentry Investment Management LLC bought a new position in PROCEPT BioRobotics in the 3rd quarter valued at $120,000. Hedge funds and other institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Price Performance

PRCT traded up $4.18 during trading on Monday, reaching $97.78. 544,744 shares of the company were exchanged, compared to its average volume of 656,941. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The company has a market cap of $5.10 billion, a price-to-earnings ratio of -48.63 and a beta of 1.01. PROCEPT BioRobotics Co. has a 12-month low of $33.45 and a 12-month high of $103.81. The company's 50-day moving average is $82.41 and its two-hundred day moving average is $72.62.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Monday, October 28th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.09. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The company had revenue of $58.40 million during the quarter, compared to analyst estimates of $53.30 million. During the same period last year, the business earned ($0.51) earnings per share. PROCEPT BioRobotics's revenue was up 66.4% compared to the same quarter last year. Research analysts forecast that PROCEPT BioRobotics Co. will post -1.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PRCT. Wells Fargo & Company increased their price target on shares of PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an "overweight" rating in a research report on Friday, August 2nd. TD Cowen raised their price target on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a "buy" rating in a research note on Monday, September 16th. Bank of America upped their price objective on PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a "buy" rating in a research note on Thursday, August 22nd. Truist Financial reissued a "buy" rating and issued a $105.00 target price (up from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. Finally, Jefferies Financial Group began coverage on PROCEPT BioRobotics in a research note on Thursday, November 14th. They issued a "hold" rating and a $95.00 target price on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $89.50.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 35,220 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $76.12, for a total value of $2,680,946.40. Following the completion of the sale, the director now directly owns 23,963 shares of the company's stock, valued at $1,824,063.56. The trade was a 59.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Reza Zadno sold 288,461 shares of the company's stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $91.00, for a total transaction of $26,249,951.00. Following the sale, the chief executive officer now owns 258,445 shares of the company's stock, valued at approximately $23,518,495. The trade was a 52.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 561,773 shares of company stock valued at $49,073,125. 17.40% of the stock is owned by corporate insiders.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).